The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation

Blood

Volumn 111, Issue 7, 2008, Pages 3901-3902

  Hamadani, Mehdi ^a   Awan, Farrukh T ^a   Devine, Steven M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KAPLAN MEIER METHOD; LETTER; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; TH2 CELL; WHOLE BODY RADIATION; ACUTE DISEASE; ALLOTRANSPLANTATION; DISEASE FREE SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA; MIDDLE AGED; RETROSPECTIVE STUDY; SURVIVAL RATE;

ACUTE DISEASE; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKEMIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 43549086236     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-132050     Document Type: Letter

References (6)

1. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109:4119-4126.
2. Zeiser R, Youssef S, Baker J, et al. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007;110:4588-4598.
3. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003;170:1524-1530.
4. Youssef S, Stüve 0,Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes aTh2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420:78-84.
5. Hori A, Kanda Y, Goyama S, et al. A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation. 2005;79:372-374.
6. Przepiorka D, Weisdorf D. Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995:15:825-828.